Loading
A Swedish trial found that cheap aspirin roughly halved recurrence in colorectal cancer patients with a particular tumour mutation. Nobody is going to market it, so health systems must adopt it deliberately.
The ALASCCA randomised trial (reported 2025) found that low-dose aspirin for three years reduced recurrence in patients with PIK3CA-mutated colorectal cancer after surgery, following earlier observational signals, while broader trials (ASCOLT, Add-Aspirin ongoing) have shown smaller or no unselected effects. Because aspirin has no sponsor, the result risks slow and uneven adoption. The proposal is a coordinated implementation programme: guideline inclusion (ESMO, NCCN), routine PIK3CA testing at diagnosis as a reimbursed test, third-party label filings where pathways exist, and an implementation registry capturing uptake and outcomes.
People with Lynch syndrome should be offered daily aspirin, which roughly halves bowel cancer risk with a delayed and durable effect. Whether a lower dose (as tested in CAPP3) is as effective, and whether the finding extends to the general population, are separate questions.
One of the most cited reviews Europe PMC returns for PIK3CA in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for PIK3CA in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for PIK3CA in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years, Aspirin for cancer prevention and adjuvant therapy, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Colorectal cancer.
Shares European Society for Medical Oncology (ESMO), No incentive to repurpose cheap drugs, Knowledge reaches practice too slowly.
Shares CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years, Aspirin for cancer prevention and adjuvant therapy.
Shares Aspirin for cancer prevention and adjuvant therapy, No incentive to repurpose cheap drugs, Colorectal cancer.
Shares Aspirin for cancer prevention and adjuvant therapy, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, No incentive to repurpose cheap drugs, Colorectal cancer.
Shares No incentive to repurpose cheap drugs, Knowledge reaches practice too slowly.
Shares Aspirin for cancer prevention and adjuvant therapy, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers.
Shares European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.